Experimental pathology

Lindus Health Launches "All-In-One Metabolic CRO" Offering to Accelerate and Enhance Metabolic Clinical Trials

Retrieved on: 
Tuesday, March 5, 2024
Diabetes, Metabolism, Electronic data capture, Lindus, Ethics, Pi, Obesity, MIT, CTMS, Data collection, Conditional sentence, DSM-IV codes, Entrepreneurship, Prevalence, Health information management, University, Therapy, Pathology, Patient, Marriage, Experimental pathology, Clinical trial, Carel le Roux, NASH, EDC, Electronic health record, Research, Pharmaceutical industry

This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

Key Points: 
  • This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.
  • "Our All-in-One Metabolic CRO offering is designed to streamline study activities at every stage of research.
  • Lindus carries a site team with extensive resumes in the metabolic study execution that cover roles across PIs, CRCs, and more.
  • Lindus Health's all-encompassing Metabolic CRO offering empowers metabolic disease sponsors to run more timely and successful clinical trials while enhancing patient experience.

ADEA Announces 2023-24 Fellows of Its Inaugural Council of Deans Fellowship

Retrieved on: 
Wednesday, June 21, 2023
Health, Other Education, University, Dental, Education, Archives of Oral Biology, Experimental pathology, DRS, CWRU, Maryland School, Chemistry, Fellows, Research, Postgraduate education, CODA, Al-Ghad International Health Sciences Colleges, Prosthodontics, Exhibition, M.A, Indiana University School of Dentistry, Harvard School of Dental Medicine, Dean (education), Oral medicine, Pathology, Case Western Reserve University School of Medicine, Oral and maxillofacial pathology, Sacroiliac joint, University of Siena, ADEA, Western University, American Academy, Association of Christian Universities and Colleges in Asia, Otorhinolaryngology, Diplom, University of Maryland School of Dentistry, Dentistry, New York University, Orofacial pain, Medicine

ADEA is pleased to announce the inaugural class of the ADEA Council of Deans Fellowship (ADEA CDF), a new leadership development program that launched in May.

Key Points: 
  • ADEA is pleased to announce the inaugural class of the ADEA Council of Deans Fellowship (ADEA CDF), a new leadership development program that launched in May.
  • The ADEA CDF is a year-long, part-time fellowship aimed at creating a diverse pipeline of future leaders who will assume roles as dental school deans and other senior university leadership positions.
  • The ADEA CDF will increase the number of qualified candidates for deanships and equip them with the skills and experiences to help them succeed.
  • The ADEA CDF Program Director is Dean Emeritus Steven Friedrichsen, D.D.S., of Western University of Health Sciences College of Dental Medicine.

Jasper Therapeutics Announces Appointment of Stephen J. Galli, M.D. to Scientific Advisory Board

Retrieved on: 
Wednesday, May 10, 2023
Asthma, MGH, Microbiology, Beth Israel Deaconess Medical Center, Basophil, Food allergy, Genomics, International Chinese Language Program, United States Air Force Scientific Advisory Board, Stanford University, Personalized medicine, Atopic dermatitis, Experimental pathology, Research, B cell, Harvard College, Cell, Assistant, Harvard Medical School, MDS, Galli, Immunity, Geisel School of Medicine, Division, Transplant, Executive Committee, Stanford University School of Medicine, Biology, Faculty, Knowledge, Immunology, BMS, S-1 Executive Committee, Hospital, Health, CD117, Massachusetts General Hospital, Therapy, Stanford Institutes of Medicine Summer Research Program, Anatomical pathology, Disease, Pathology

Professor at Stanford Medicine, to the company’s Scientific Advisory Board.

Key Points: 
  • Professor at Stanford Medicine, to the company’s Scientific Advisory Board.
  • “We are thrilled to welcome Dr. Galli to our Scientific Advisory Board,” said Ron Martell, CEO of Jasper Therapeutics.
  • “Dr.
  • Galli is an internationally recognized researcher who has made pioneering contributions to the field of immunology.

Foundery and the University of Arizona Sign Master Agreement to Translate Novel Discoveries into Transformational Immunotherapies

Retrieved on: 
Thursday, April 6, 2023
Partnership, Drug development, University, Biotechnology, Experimental pathology, University of California, Research, Tech, Translation, Invention, Professor, Pathology, SAN, TLA, IND, Pharmaceutical industry, Management, The Foundery

The partnership is designed to support research and create opportunities to develop and commercialize new immunotherapeutics.

Key Points: 
  • The partnership is designed to support research and create opportunities to develop and commercialize new immunotherapeutics.
  • “Our venture studio model is structured to identify therapeutic opportunities emerging from fundamental research in immunology conducted by leading scientists,” said Michel Streuli, Ph.D., Chief Executive Officer and Co-Founder of Foundery.
  • The agreement with UArizona is the second master agreement that we have announced this year.
  • We anticipate more to come as the academic research community better understands our venture model and how it benefits all our constituencies.”

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Retrieved on: 
Thursday, March 9, 2023
Hemolysis, University of Cape Town, PRC2, Research, FDA, G&A, Telephone, University, FSHD, Fetal hemoglobin, Biomarker, Al-Abid, IND, Letter, Conference, Interim, REACH, Bone marrow, Cohort, Therapy, SCD, GSK plc, Risk, CMO, Communication, Pathology, Bachelor, Experimental pathology, Harvard University, Sickle cell disease, Conference call, Webcast, Collaboration, Merck & Co., Patient, Lundbeck, Surgery, Life insurance, Pharmaceutical industry, Cryptocurrency, Dietary supplement, Merck, MD, Bachelor of Medicine, Bachelor of Surgery, HBF, Agency, Medicine, Doctor of Philosophy, Fulcrum, Biochemistry, Science

The Agency requested that Fulcrum further define the population where the potential benefit of continued treatment with FTX-6058 outweighs potential risk.

Key Points: 
  • The Agency requested that Fulcrum further define the population where the potential benefit of continued treatment with FTX-6058 outweighs potential risk.
  • Collaboration Revenue: Collaboration revenue was $0.7 million for the fourth quarter of 2022 as compared to $5.1 million for the fourth quarter of 2021.
  • Net Loss: Net loss was $26.1 million for the fourth quarter of 2022, as compared to a net loss of $23.5 million for the fourth quarter of 2021.
  • ET to review the fourth quarter and full year 2022 recent business highlights and financial results.

Resolve Biosciences Expands Meridian Molecular Cartography™ Service Program for Virtually Any Species or Tissue Type at AGBT 2023

Retrieved on: 
Monday, February 6, 2023
Biotechnology, Health, Genetics, Science, Research, DNA, Cartography, Pathology, Developmental biology, University of Pittsburgh Medical Center, Workflow, Acceleration, Data analysis, Neurology, Experimental pathology, University, Laboratory, Mass meeting, Manuscript, Multimedia, Spatial analysis, Gene expression, Medical imaging, Meridian, MD, Suite

Resolve Biosciences , the pioneer in Molecular Cartography™ technology, today announced the expansion of its end-to-end Meridian service offering for spatial transcriptomics data.

Key Points: 
  • Resolve Biosciences , the pioneer in Molecular Cartography™ technology, today announced the expansion of its end-to-end Meridian service offering for spatial transcriptomics data.
  • The company will unveil its expanded Meridian service program and discuss the latest advances in Molecular Cartography technology at this week’s Advances in Genome Biology and Technology (AGBT) General Meeting.
  • “With our expanded Meridian service offering, more customers can now apply the full power of our Molecular Cartography system to virtually any species or tissue type, including FFPE.
  • Resolve will begin offering FFPE tissue capabilities as part of its Meridian service program and will add the feature to its commercial Molecular Cartography systems later this year.

Experimental Treatment Approach Counters Allergic Asthma without Weakening Flu Defenses

Retrieved on: 
Friday, October 7, 2022
Tao, National Institutes of Health, Medical research, NYU, New York University Grossman School of Medicine, Novo Nordisk Foundation, Science Advances, National, Icahn School of Medicine at Mount Sinai, Lung, German Research Foundation, Pathology, Virus, Feces, Infection, Inflammation, Breathe Me, Mouse, Center, Department, Mount Sinai School, Korea Disease Control and Prevention Agency, Wang, Asthma, Child, Cough, Society, Calcium, Cell, ORAI1, American Society of Hematology, Allergen, Membrane protein, St. Jude Children's Research Hospital, Immunoglobulin E, NYU Langone Health, Wheeze, Acute pancreatitis, Eosinophil, Gene expression, Experimental pathology, Disease, CRAC, Cytokine, Pain scale, MD, Doctor of Philosophy, Bernard Levin, COVID-19, Vaccine, Pharmaceutical industry, Science, T helper cell, New York University

Blocking signals sent through this channel with an investigational new drug called a CRAC channel inhibitor had a similar effect.

Key Points: 
  • Blocking signals sent through this channel with an investigational new drug called a CRAC channel inhibitor had a similar effect.
  • Allergic asthma is characterized by increased type 2 (T2) inflammation, which involves a subset of T cells called T helper (Th) 2 cells, say the study authors.
  • Without calcium entering through CRAC channels, T cells are unable to become Th2 cells and produce the cytokines that cause allergic asthma, the authors say.
  • "This suggests CRAC channel inhibition as a promising, potential future treatment approach for allergic airway disease."

AAV5 DetectCDx™ Kit Is First ARUP Test Developed to Support a New Therapy

Retrieved on: 
Tuesday, September 27, 2022
ARUP Laboratories, VIII, Laboratory, Factor VIII, Cdx, MD, SALT, University, Haemophilia, European Commission, Experimental pathology, BioMarin Pharmaceutical, CMA, Clinical trial, Partnership, Patient, CE, Hercules, Doctor of Philosophy, ARUP, BLA, European Commission–AstraZeneca COVID-19 vaccine dispute, Royal commission, Union, Multimedia, Medical device, Pharmaceutical industry, EU, Pathology

The AAV5 DetectCDx Kit was developed by ARUP Laboratories' PharmaDx Group in partnership with BioMarin.

Key Points: 
  • The AAV5 DetectCDx Kit was developed by ARUP Laboratories' PharmaDx Group in partnership with BioMarin.
  • The AAV5 DetectCDx Kit was developed by ARUP Laboratories' PharmaDx Group in partnership with BioMarin to help identify patients who are eligible for treatment with ROCTAVIAN.
  • The AAV5 DetectCDx Kit is already authorized for use in Europe, having received its Conformit Europenne (CE) mark in January 2022.
  • When clinicians begin using the AAV5 DetectCDx Kit, the companion diagnostic will become the first ARUP-developed test to be used in Europe.

Cambrian BioPharma Announces its Scientific Advisory Board led by Two Veteran R&D Executives

Retrieved on: 
Wednesday, September 14, 2022
Actinium, Knowledge, University of Manchester, Sir, VP, Health, Therapy, Hermes L. Ames, Ageing, Twitter, Longevity, Research, Hospital, United States Air Force Scientific Advisory Board, GlaxoSmithKline, LinkedIn, Schering-Plough, Experimental pathology, UK Academy for Information Systems, UMDS, Review, Bayer, Secondary research, University of Strathclyde, Program, VNAR, Royal Society, Medicine, CEO, Neuroscience Research Australia, Knowledge management, Quality of life, Bachelor of Science, SAB, University of Wales, Doctor of Philosophy, Science, Wyeth, University College London, Pathology, R, Multimedia, University, Neurology, EVP, Merck, SVP, View, Guy's Hospital, Discovery, Management, Pharmaceutical industry, Organon, Neuroscience, Allergan

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces its Scientific Advisory Board (SAB) and appointment of C. David Nicholson, PhD and Frank S. Walsh, PhD to lead.

Key Points: 
  • NEW YORK, Sept. 14, 2022 /PRNewswire/ -- Cambrian BioPharma , a multi-asset longevity biotech, today announces its Scientific Advisory Board (SAB) and appointment of C. David Nicholson, PhD and Frank S. Walsh, PhD to lead.
  • SAB reports are shared with individual pipeline companies for consideration in project strategy and planning and are also shared with the Cambrian BioPharma Board of Directors.
  • Moving forward Cambrian may add further SAB members or ad-hoc advisors as its pipeline grows and matures.
  • "Cambrian BioPharma is honored to have two highly experienced R&D executives to assist with our pursuit of expanding healthspan in the 21st century," said Brenton L. Saunders, Cambrian BioPharma Board of Directors.

ORION BIOTECHNOLOGY ADDS GPCR EXPERT TO ITS SCIENTIFIC ADVISORY BOARD

Retrieved on: 
Tuesday, July 5, 2022
Pathology, LinkedIn, Chemokine, GLOBE, Orion, Queen Mary University of London, Growth, Cancer, Semmelweis University, Gq alpha subunit, SAB, Pharmacology, G protein-coupled receptor, Inflammation, Experimental pathology, Therapy, National Cancer Institute, Novartis Institute for Tropical Diseases, National, Drug discovery, Fine chemical, GPCR

Ottawa, Canada, July 05, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery and development company targeting previously-undruggable G Protein-Coupled Receptors (GPCRs), today announced that Dr. Antal Rot, a world-renowned expert in the role of chemokines in inflammation, has joined Orions scientific advisory board (SAB).

Key Points: 
  • Ottawa, Canada, July 05, 2022 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a drug discovery and development company targeting previously-undruggable G Protein-Coupled Receptors (GPCRs), today announced that Dr. Antal Rot, a world-renowned expert in the role of chemokines in inflammation, has joined Orions scientific advisory board (SAB).
  • at the Semmelweis University in Budapest, Hungary before completing his post-doctoral research training at the National Cancer Institute (Frederick, USA) in the lab of Edward Leonard.
  • Orion Biotechnology Canada Ltd. is unlocking the therapeutic potential of previously-undruggable G Protein-Coupled Receptors (GPCRs).
  • With its team of world-renowned experts in GPCR pharmacology and peptide/protein engineering, Orion Biotechnology is well-positioned to improve patient outcomes.